HC Wainwright Has Bearish Estimate for DTIL Q3 Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – Equities researchers at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for shares of Precision BioSciences in a report released on Wednesday, August 12th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($1.19) for the quarter, down from their prior forecast of ($0.58). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($3.47) EPS, FY2027 earnings at ($1.55) EPS, FY2028 earnings at ($0.75) EPS and FY2029 earnings at ($0.95) EPS.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%.

Several other equities analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precision BioSciences in a research note on Wednesday, August 5th. Wall Street Zen downgraded Precision BioSciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. JonesTrading reiterated a “buy” rating and set a $30.00 price target on shares of Precision BioSciences in a research report on Friday, April 17th. Finally, Oppenheimer started coverage on shares of Precision BioSciences in a research note on Tuesday, June 9th. They set an “outperform” rating and a $20.00 target price on the stock. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Precision BioSciences has an average rating of “Moderate Buy” and an average target price of $32.25.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $7.30 on Friday. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $9.62. The business’s 50 day moving average price is $7.44 and its 200 day moving average price is $6.44. The firm has a market cap of $201.48 million, a P/E ratio of -2.61 and a beta of 1.27.

Institutional Investors Weigh In On Precision BioSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new stake in Precision BioSciences in the 2nd quarter valued at about $467,000. Bank of America Corp DE boosted its position in Precision BioSciences by 167.6% in the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock valued at $151,000 after buying an additional 17,172 shares during the period. Quantinno Capital Management LP acquired a new position in shares of Precision BioSciences in the first quarter worth $104,000. Octagon Capital Advisors LP raised its stake in shares of Precision BioSciences by 16.6% in the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after acquiring an additional 318,737 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new position in Precision BioSciences during the 1st quarter worth $3,289,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.